GNCAQ — Genocea Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$12.49m
- $1.64m
Annual cashflow statement for Genocea Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -56.7 | -27.8 | -39 | -43.7 | -33.2 |
| Depreciation | |||||
| Non-Cash Items | 5.74 | -9.57 | 1.44 | -2.24 | -16 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.85 | -4.94 | -1.32 | 3.17 | 2.27 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -47.6 | -41.2 | -37.7 | -41.7 | -45.4 |
| Capital Expenditures | -1.18 | -0.241 | -1.14 | -2.58 | -3.29 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 36.1 | 0.11 | 0.048 | 0.03 | 0.08 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 34.9 | -0.131 | -1.09 | -2.56 | -3.21 |
| Financing Cash Flow Items | -0.197 | 52.4 | 0.13 | — | -0.377 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2.46 | 55.5 | 52.9 | 83.8 | 5.96 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -15.2 | 14.1 | 14.1 | 39.6 | -42.6 |